Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Steven J. Bots, Sabine Kuin, Cyriel Y. Ponsioen, Krisztina B. Gecse, Marjolijn Duijvestein, Geert R. D’Haens & Mark Löwenberg. (2019) Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy. Scandinavian Journal of Gastroenterology 54:3, pages 281-288.
Read now
Read now
Sine Buhl, Märta Kristina Borghede, Jørn Brynskov, Casper Steenholdt, Maria Rasmussen & Mark Andrew Ainsworth. (2018) Outcome of continued infliximab therapy in Crohn’s disease patients with response but without remission after one year of infliximab – a retrospective cohort study. Scandinavian Journal of Gastroenterology 53:8, pages 930-937.
Read now
Read now
Pauliina Molander, Martti Färkkilä, Helena Kemppainen, Timo Blomster, Airi Jussila, Harri Mustonen & Taina Sipponen. (2017) Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 52:3, pages 284-290.
Read now
Read now
Lieven Pouillon, Peter Bossuyt & Laurent Peyrin-Biroulet. (2016) Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion on Biological Therapy 16:10, pages 1277-1290.
Read now
Read now
A. S. Strik, S. J. A. Bots, G. D’Haens & M. Löwenberg. (2016) Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology 9:3, pages 429-439.
Read now
Read now
Martin Bortlik, Dana Duricova, Nadezda Machkova, Veronika Hruba, Martin Lukas, Katarina Mitrova, Igor Romanko, Vladislav Bina, Karin Malickova, Martin Kolar & Milan Lukas. (2016) Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scandinavian Journal of Gastroenterology 51:2, pages 196-202.
Read now
Read now
Jon Florholmen. (2015) Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. Scandinavian Journal of Gastroenterology 50:1, pages 43-52.
Read now
Read now
Klaudia Farkas, Péter László Lakatos, Ferenc Nagy, Zoltán Szepes, Pál Miheller, Mária Papp, Károly Palatka, Anita Bálint, Renáta Bor, Tibor Wittmann & Tamás Molnár. (2013) Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scandinavian Journal of Gastroenterology 48:12, pages 1394-1398.
Read now
Read now
Dario Sorrentino, Sandy Fogel & Johan Van den Bogaerde. (2013) Surgery for Crohn’s disease and anti-TNF agents: the changing scenario. Expert Review of Gastroenterology & Hepatology 7:8, pages 689-700.
Read now
Read now
Renathe Rismo, Trine Olsen, Guanglin Cui, Eyvind J. Paulssen, Ingrid Christiansen, Knut Johnsen, Jon Florholmen & Rasmus Goll. (2013) Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease. Scandinavian Journal of Gastroenterology 48:3, pages 311-319.
Read now
Read now
Vera Kandror Denmark & Lloyd Mayer. (2013) Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update. Expert Review of Clinical Immunology 9:1, pages 77-92.
Read now
Read now
Gia M Bradley & Maria Oliva-Hemker. (2012) Infliximab for the treatment of pediatric ulcerative colitis. Expert Review of Gastroenterology & Hepatology 6:6, pages 659-665.
Read now
Read now
Articles from other publishers (65)
Annemay M. H. Stoker, Leslie Logghe, Mirjam C. M. van der Ende-van Loon, Erik J. Schoon, Ramon-Michel Schreuder, Arnold Stronkhorst & Lennard P. L. Gilissen. (2023) Relapse rates after withdrawal versus maintaining biologic therapy in IBD patients with prolonged remission. Clinical and Experimental Medicine.
Crossref
Crossref
Cong Dai, Yi-Nuo Wang, Wen-Ning Tian, Yu-Hong Huang & Min Jiang. (2023) Long-term clinical outcomes after the discontinuation of anti-TNF agents in patients with inflammatory bowel disease: a meta-analysis. Revista Española de Enfermedades Digestivas.
Crossref
Crossref
Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, Steven Bots, Robert Downey, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Xavier Roblin, Klaudia Farkas, Jakob B. Seidelin, Marjolijn Duijvestein, Geert R. D’Haens, Annemarie C. de Vries, Annemarie C. de Vries, Renske W.M. Pauwels, C. Janneke van der Woude, Daan Nieboer, Ewout W. Steyerberg, Jasmijn A.M. Sleutjes, Marjolijn Duijvestein, Geert R. D’Haens, María J. Casanova, Javier P. Gisbert, Nick A. Kennedy, Charlie W. Lees, Edouard Louis, Tamás Molnár, Kata Szántó, Eduardo Leo, José M. García-Ortiz, Robert Downey, Alenka J. Brooks, Peter J. Hamlin, Shaji Sebastian, Alan J. Lobo, Milan Lukas, Wei C. Lin, Aurelien Amiot, Cathy Lu, Levinus (Leo) A. Dieleman, Xavier Roblin, Shomron Ben-Horin, Klaudia Farkas, Jakob B. Seidelin, Casper Steenholdt & Steven Bots. (2022) Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn’s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology 20:8, pages 1671-1686.e16.
Crossref
Crossref
Sine Buhl, Casper Steenholdt, Jørn Brynskov, Katrine Risager Christensen, Maria Dorn-Rasmussen, Ole Østergaard Thomsen, Klaus Bendtzen, Tobias Wirenfeldt Klausen, Jens Frederik Dahlerup, Niels Thorsgaard, Jørgen Jahnsen, Akbar Molazahi, Natalia Pedersen, Jens Kjeldsen, Sven Almer, Eva Efsen Dahl, Ida Vind, Annett Gerhardt Cannon, Jan Marsal, Taina Sipponen, Jørgen Steen Agnholt, Hendrika Adriana Linda Kievit, Synnøve Louise Aure, Lars Martinsen, Svetlana Meisner, Jane Møller Hansen & Mark Andrew Ainsworth. (2022) Discontinuation of Infliximab Therapy in Patients with Crohn’s Disease. NEJM Evidence 1:8.
Crossref
Crossref
Luca Scarallo, Giulia Bolasco, Jacopo Barp, Martina Bianconi, Monica di Paola, Michele Di Toma, Sara Naldini, Monica Paci, Sara Renzo, Flavio Labriola, Salvatore De Masi, Patrizia Alvisi & Paolo Lionetti. (2022) Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission. Inflammatory Bowel Diseases 28:2, pages 183-191.
Crossref
Crossref
Taku Kobayashi. (2022) Stopping Anti-TNF in CD Remitters: Cons. Inflammatory Intestinal Diseases 7:1, pages 59-63.
Crossref
Crossref
Joseph Meredith, Paul Henderson, David C. Wilson & Richard K. Russell. (2021) Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease—A Review of the Evidence. Frontiers in Pediatrics 9.
Crossref
Crossref
Joo Hye Song, Eun Ae Kang, Soo-Kyung Park, Sung Noh Hong, You Sun Kim, Ki Bae Bang, Kyeong Ok Kim, Hong Sub Lee, Sang-Bum Kang, Seung Yong Shin, Eun Mi Song, Jong Pil Im & Chang Hwan Choi. (2021) Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor-α Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. Gut and Liver 15:5, pages 752-762.
Crossref
Crossref
Joseph Meredith, Paul Henderson, David C. Wilson, Johan Van Limbergen, Eytan WineRichard K. Russell. (2021) Withdrawal of Combination Immunotherapy in Paediatric Inflammatory Bowel Disease—An International Survey of Practice. Journal of Pediatric Gastroenterology & Nutrition 73:1, pages 54-60.
Crossref
Crossref
María José Casanova, María Chaparro, Óscar Nantes, José Manuel Benítez, María Rojas‐Feria, Jesús Castro‐Poceiro, José María Huguet, Albert Martín‐Cardona, Marta Aicart‐Ramos, Joan Tosca, María del Mar Martín‐Rodríguez, Carlos González‐Muñoza, Miriam Mañosa, Eduardo Leo‐Carnerero, Luis Javier Lamuela‐Calvo, Isabel Pérez‐Martínez, Luis Bujanda, Joaquín Hinojosa, Ramón Pajares, Federico Argüelles‐Arias, José Lázaro Pérez‐Calle, Gloria Esther Rodríguez‐González, Jordi Guardiola, Manuel Barreiro‐de Acosta & Javier P. Gisbert. (2021) Clinical outcome after anti‐tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long‐term study. Alimentary Pharmacology & Therapeutics 53:12, pages 1277-1288.
Crossref
Crossref
Taku Kobayashi, Satoshi Motoya, Shiro Nakamura, Takayuki Yamamoto, Masakazu Nagahori, Shinji Tanaka, Tadakazu Hisamatsu, Fumihito Hirai, Hiroshi Nakase, Kenji Watanabe, Takayuki Matsumoto, Masanori Tanaka, Takayuki Abe, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Shingo Kato, Atsushi Maemoto, Minoru Matsuura, Ryosuke Sakemi, Makoto Sasaki, Tomoyuki Tsujikawa, Motohiro Esaki, Norimasa Fukata, Kazuya Kitamura, Sakiko Hiraoka, Ryota Hokari, Shunji Ishihara, Tsutomu Mizoshita, Yuji Naito, Fumio Omata, Masayuki Saruta & Takuya Yoshino. (2021) Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial. The Lancet Gastroenterology & Hepatology 6:6, pages 429-437.
Crossref
Crossref
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon & Yun Mi Yu. (2021) Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. Therapeutic Advances in Chronic Disease 12, pages 204062232110419.
Crossref
Crossref
Dóra Dohos, Lilla Hanák, Zsolt Szakács, Szabolcs Kiss, Andrea Párniczky, Bálint Erőss, Piroska Pázmány, Péter Hegyi & Patrícia Sarlós. (2020) Systematic review with meta‐analysis: the effects of immunomodulator or biological withdrawal from mono‐ or combination therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 53:2, pages 220-233.
Crossref
Crossref
Catarina Frias Gomes, Thomas P Chapman & Jack Satsangi. (2020) De-escalation of medical therapy in inflammatory bowel disease. Current Opinion in Pharmacology 55, pages 73-81.
Crossref
Crossref
Derek H. W. LittleSahar TabatabavakiliSeth R. ShafferGeoffrey C. NguyenAdam V. WeizmanLaura E. Targownik. (2020) Effectiveness of Dose De-escalation of Biologic Therapy in Inflammatory Bowel Disease: A Systematic Review. American Journal of Gastroenterology 115:11, pages 1768-1774.
Crossref
Crossref
Robert P. Hirten, Peter L. Lakatos, Jonas Halfvarson & Jean Frederic Colombel. (2020) A User’s Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 18:6, pages 1336-1345.
Crossref
Crossref
Thomas P Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2020) De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 5:1, pages 63-79.
Crossref
Crossref
Sandra Bohn Thomsen, Marianne Kiszka-Kanowitz, Klaus Theede, Lise Lotte Gluud & Anette Mertz Nielsen. (2018) Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn’s disease. European Journal of Gastroenterology & Hepatology 30:10, pages 1155-1158.
Crossref
Crossref
Samuel O. Adegbola, Kapil Sahnan, Janindra Warusavitarne, Ailsa Hart & Philip Tozer. (2018) Anti-TNF Therapy in Crohn’s Disease. International Journal of Molecular Sciences 19:8, pages 2244.
Crossref
Crossref
Edouard Louis. (2018) Stopping Biologics in IBD—What Is the Evidence?. Inflammatory Bowel Diseases 24:4, pages 725-731.
Crossref
Crossref
Catherine Reenaers, Jean-Yves Mary, Maria Nachury, Yoram Bouhnik, David Laharie, Matthieu Allez, Mathurin Fumery, Aurélien Amiot, Guillaume Savoye, Romain Altwegg, Martine Devos, Georgia Malamut, Arnaud Bourreille, Bernard Flourie, Philippe Marteau, Lucine Vuitton, Benoît Coffin, Stéphanie Viennot, Jérôme Lambert, Jean-Frédéric Colombel & Edouard Louis. (2018) Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission. Clinical Gastroenterology and Hepatology 16:2, pages 234-243.e2.
Crossref
Crossref
Glen Doherty, Konstantinos H Katsanos, Johan Burisch, Matthieu Allez, Konstantinos Papamichael, Andreas Stallmach, Ren Mao, Ingrid Prytz Berset, Javier P Gisbert, Shaji Sebastian, Jarosław Kierkuś, Loris Lopetuso, Edyta Szymanska & Edouard Louis. (2018) European Crohn’s and Colitis Organisation Topical Review on Treatment Withdrawal [‘Exit Strategies’] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 12:1, pages 17-31.
Crossref
Crossref
Shomron Ben-Horin, Ren Mao, Yun Qiu & Minhu Chen. (2018) Discontinuation of Biological Treatments in Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 52:1, pages 6-12.
Crossref
Crossref
Hang Hock Shim & Cynthia H. Seow. 2018. Treatment of Inflammatory Bowel Disease with Biologics. Treatment of Inflammatory Bowel Disease with Biologics
141
162
.
David B. AlexanderMasaaki IigoMohamed AbdelgiedKeiji OzekiSatoshi TanidaTakashi JohSatoru TakahashiHiroyuki Tsuda. (2017) Bovine lactoferrin and Crohn’s disease: a case study. Biochemistry and Cell Biology 95:1, pages 133-141.
Crossref
Crossref
Wei-Chen LinJen-Wei ChouHsu-Heng YenWen-Hung HsuHung-Hsin LinJen-Kou LinChiao-Hsiung ChuangTien-Yu HuangHorng-Yuan WangShu-Chen WeiJau-Min Wong. (2017) Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study. Intestinal Research 15:4, pages 487.
Crossref
Crossref
Masanao Nasuno, Maki Miyakawa, Hiroki Tanaka & Satoshi Motoya. (2017) Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study. Digestion 95:1, pages 67-71.
Crossref
Crossref
Kay-Martin Johnsen, Rasmus Goll, Vegard Hansen, Trine Olsen, Renathe Rismo, Richard Heitmann, Mona D. Gundersen, Jan M. Kvamme, Eyvind J. Paulssen, Hege Kileng, Knut Johnsen & Jon Florholmen. (2017) Repeated intensified infliximab induction – results from an 11-year prospective study of ulcerative colitis using a novel treatment algorithm. European Journal of Gastroenterology & Hepatology 29:1, pages 98-104.
Crossref
Crossref
Jean-Frederic Colombel, Neeraj Narula & Laurent Peyrin-Biroulet. (2017) Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. Gastroenterology 152:2, pages 351-361.e5.
Crossref
Crossref
M J Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, M Rojas-Feria, A Jauregui-Amezaga, S García-López, J M Huguet, F Arguelles-Arias, M Aicart, I Marín-Jiménez, M Gómez-García, F Muñoz, M Esteve, L Bujanda, X Cortés, J Tosca, J R Pineda, M Mañosa, J Llaó, J Guardiola, I Pérez-Martínez, C Muñoz, Y González-Lama, J Hinojosa, J M Vázquez, M P Martinez-Montiel, G E Rodríguez, R Pajares, M F García-Sepulcre, A Hernández-Martínez, J L Pérez-Calle, B Beltrán, D Busquets, L Ramos, F Bermejo, J Barrio, M Barreiro-de Acosta, O Roncedo, X Calvet, D Hervías, F Gomollón, M Domínguez-Antonaya, G Alcaín, B Sicilia, C Dueñas, A Gutiérrez, R Lorente-Poyatos, M Domínguez, S Khorrami, C Taxonera, A Rodríguez-Pérez, A Ponferrada, M Van Domselaar, M L Arias-Rivera, O Merino, E Castro, J M Marrero, M Martín-Arranz, B Botella, L Fernández-Salazar, D Monfort, V Opio, A García-Herola, M Menacho, Ramírez-de P la Piscina, D Ceballos, P Almela, M Navarro-Llavat, V Robles-Alonso, A B Vega-López, I Moraleja, M T Novella, C Castaño-Milla, A Sánchez-Torres, J M Benítez, C Rodríguez, L Castro, E Garrido, E Domènech, E García-Planella & J P Gisbert. (2017) Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology 112:1, pages 120-131.
Crossref
Crossref
Gionata Fiorino, Pablo Navarro Cortes, Pierre Ellul, Carla Felice, Pantelis Karatzas, Marco Silva, Peter L. Lakatos, Fabrizio Bossa, Bella Ungar, Shaji Sebastian, Federica Furfaro, Konstantinos Karmiris, Konstantinos H. Katsanos, Martina Muscat, Dimitrios K. Christodoulou, Giovanni Maconi, Uri Kopylov, Fernando Magro, Gerassimos J. Mantzaris, Alessandro Armuzzi, Marta Maia Boscà-Watts, Shomron Ben-Horin, Stefanos Bonovas & Silvio Danese. (2016) Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study. Clinical Gastroenterology and Hepatology 14:10, pages 1426-1432.e1.
Crossref
Crossref
Casper Steenholdt, Klaus Bendtzen, Jørn Brynskov & Mark A. Ainsworth. (2016) Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflammatory Bowel Diseases 22:8, pages 1999-2015.
Crossref
Crossref
Carmen Muñoz Villafranca, Maria Teresa Bravo Rodríguez, Jone Ortiz de Zárate, Paz Arreba González, Iñigo García Kamiruaga, Juan Ignacio Heras Martín, Pilar Cabezudo Gil & Víctor Orive Cura. (2016) Evolución clínica tras la suspensión de infliximab en pacientes con colitis ulcerosa en remisión profunda. Gastroenterología y Hepatología 39:7, pages 442-448.
Crossref
Crossref
Carmen Muñoz Villafranca, Maria Teresa Bravo Rodríguez, Jone Ortiz de Zárate, Paz Arreba González, Iñigo García Kamiruaga, Juan Ignacio Heras Martín, Pilar Cabezudo Gil & Víctor Orive Cura. (2016) Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission. Gastroenterología y Hepatología (English Edition) 39:7, pages 442-448.
Crossref
Crossref
M. Anthony Sofia & David T. Rubin. (2016) Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis. Therapeutic Advances in Gastroenterology 9:4, pages 548-559.
Crossref
Crossref
Aranzazu Jauregui Amezaga & Gert Van Assche. (2016) Practical Approaches to “Top–Down” Therapies for Crohn’s Disease. Current Gastroenterology Reports 18:7.
Crossref
Crossref
Javier P Gisbert, Alicia C Marín & María Chaparro. (2016) The Risk of Relapse after Anti-TNF Discontinuation in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. American Journal of Gastroenterology 111:5, pages 632-647.
Crossref
Crossref
Joana Torres, Marília Cravo & Jean-Frédéric Colombel. (2016) Anti-TNF Withdrawal in Inflammatory Bowel Disease. GE Portuguese Journal of Gastroenterology 23:3, pages 153-161.
Crossref
Crossref
Trine Olsen, Renathe Rismo, Mona Dixon Gundersen, Eyvind J. Paulssen, Knut Johnsen, Jan-Magnus Kvamme, Rasmus Goll & Jon Florholmen. (2016) Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis. Cytokine 79, pages 90-95.
Crossref
Crossref
Florence Le Roy, Laurent Siproudhis, Jean-François Bretagne & Guillaume Bouguen. (2016) Long-term infliximab therapy is needed for sustained steroid-free remission in patients with ulcerative colitis. Digestive and Liver Disease 48:2, pages 208-209.
Crossref
Crossref
Marcello Cintolo. (2016) Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World Journal of Gastrointestinal Pathophysiology 7:1, pages 1.
Crossref
Crossref
Joana Torres, Ray K. Boyapati, Nicholas A. Kennedy, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2015) Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 149:7, pages 1716-1730.
Crossref
Crossref
Parakkal Deepak & David H. Bruining. (2015) Update on the Medical Management of Crohn’s Disease. Current Gastroenterology Reports 17:11.
Crossref
Crossref
Ibrahim K. Onal, Yavuz Beyazit, Akif Altinbas, Mevlut Kurt & Mehmet Arhan. (2015) Maintenance therapy for Crohn’s disease. European Journal of Gastroenterology & Hepatology 27:10, pages 1115-1125.
Crossref
Crossref
J. P. Gisbert, A. C. Marín & M. Chaparro. (2015)
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti‐
TNF
therapy
. Alimentary Pharmacology & Therapeutics 42:4, pages 391-405.
Crossref
Crossref
S. Ben‐Horin, Y. Chowers, B. Ungar, U. Kopylov, R. Loebstein, B. Weiss, R. Eliakim, E. Del Tedesco, S. Paul & X. Roblin. (2015)
Undetectable anti‐
TNF
drug levels in patients with long‐term remission predict successful drug withdrawal
. Alimentary Pharmacology & Therapeutics 42:3, pages 356-364.
Crossref
Crossref
Konstantinos Papamichael, Niels Vande Casteele, Ann Gils, Sophie Tops, Scott Hauenstein, Sharat Singh, Fred Princen, Gert Van Assche, Paul Rutgeerts, Severine Vermeire & Marc Ferrante. (2015) Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission. Clinical Gastroenterology and Hepatology 13:6, pages 1103-1110.
Crossref
Crossref
Satoshi Tanida. (2015) Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World Journal of Gastroenterology 21:29, pages 8776.
Crossref
Crossref
Konstantinos Papamichael. (2015) Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease. World Journal of Gastroenterology 21:16, pages 4773.
Crossref
Crossref
Anita Annaházi & Tamás Molnár. (2015) Optimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug Withdrawal. Gastroenterology Research and Practice 2015, pages 1-18.
Crossref
Crossref
Daniel J. Stein. 2015. Inflammatory Bowel Disease. Inflammatory Bowel Disease
91
98
.
Sine Schnoor Buhl, Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Klaus Bendtzen & Mark Andrew Ainsworth. (2014) Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open 4:12, pages e005887.
Crossref
Crossref
Cong Dai, Wei-Xin Liu, Min Jiang & Ming-Jun Sun. (2014) Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy. PLoS ONE 9:10, pages e110797.
Crossref
Crossref
B. Pariente & D. Laharie. (2014) Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Alimentary Pharmacology & Therapeutics 40:4, pages 338-353.
Crossref
Crossref
Armelle Chauvin, Aurelie Le Thuaut, Mehdi Belhassan, Yann Le Baleur, Farida Mesli, Sylvie Bastuji-Garin, Jean Charles Delchier & Aurelien Amiot. (2014) Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study. Digestive and Liver Disease 46:8, pages 695-700.
Crossref
Crossref
Michel H. Maillard, Murielle Bortolotti, John-Paul Vader, Christian Mottet, Alain Schoepfer, Jean-Jacques Gonvers, Bernard Burnand, Florian Froehlich, Pierre Michetti & Valérie Pittet. (2014) Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. Journal of Crohn's and Colitis 8:8, pages 825-834.
Crossref
Crossref
Pauliina Molander, Martti Färkkilä, Ari Ristimäki, Kimmo Salminen, Helena Kemppainen, Timo Blomster, Ritva Koskela, Airi Jussila, Henna Rautiainen, Markku Nissinen, Johanna Haapamäki, Perttu Arkkila, Urpo Nieminen, Juha Kuisma, Jari Punkkinen, Kaija-Leena Kolho, Harri Mustonen & Taina Sipponen. (2014) Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?. Journal of Crohn's and Colitis.
Crossref
Crossref
Pauliina Molander, Martti Färkkilä, Kimmo Salminen, Helena Kemppainen, Timo Blomster, Ritva Koskela, Airi Jussila, Henna Rautiainen, Markku Nissinen, Johanna Haapamäki, Perttu Arkkila, Urpo Nieminen, Juha Kuisma, Jari Punkkinen, Kaija-Leena Kolho, Harri Mustonen & Taina Sipponen. (2014) Outcome After Discontinuation of TNFα-blocking Therapy in Patients with Inflammatory Bowel Disease in Deep Remission. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref
Taku Kobayashi & Toshifumi Hibi. (2014) Which makes patients happier, surgery or anti-TNF therapy?. Nature Reviews Gastroenterology & Hepatology 11:5, pages 272-273.
Crossref
Crossref
Dario Sorrentino, Peter Nash, Monica Viladomiu, Raquel Hontecillas & Josep Bassaganya-Riera. (2014) Stopping Anti-TNF Agents in Patients with Crohnʼs Disease in Remission. Inflammatory Bowel Diseases 20:4, pages 757-766.
Crossref
Crossref
Shomron Ben-Horin & Yehuda Chowers. (2014) Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nature Reviews Gastroenterology & Hepatology 11:4, pages 243-255.
Crossref
Crossref
Klaudia Farkas & Tamás Molnár. (2014) Biological Therapy in IBD—Is There Any Optimal End Point?. Health 06:11, pages 1296-1299.
Crossref
Crossref
Dario Sorrentino. (2013) State-of-the-art medical prevention of postoperative recurrence of Crohn's disease. Nature Reviews Gastroenterology & Hepatology 10:7, pages 413-422.
Crossref
Crossref
C. Steenholdt, Y. Palarasah, K. Bendtzen, A. Teisner, J. Brynskov, B. Teisner & C. H. Nielsen. (2013) Pre‐existing IgG antibodies cross‐reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 37:12, pages 1172-1183.
Crossref
Crossref
Fabrizio Bossa, Vito Annese, Maria Rosa Valvano, Anna Latiano, Giuseppina Martino, Luigia Rossi, Mauro Magnani, Orazio Palmieri, Sonja Serafini, Gianluca Damonte, Ermelinda De Santo & Angelo Andriulli. (2013) Erythrocytes-mediated Delivery of Dexamethasone 21-phosphate in Steroid-dependent Ulcerative Colitis. Inflammatory Bowel Diseases, pages 1.
Crossref
Crossref